Addex Therapeutics
| Addex Therapeutics Ltd | |
|---|---|
| legal form | Corporation |
| ISIN | CH0029850754 |
| founding | 2002 |
| Seat |
Plan-les-Ouates GE Switzerland
|
| management | Tim Dyer (Chairman of the Management Board ) André Mueller ( Chairman of the Board of Directors ) |
| Number of employees | 23 (2019) |
| sales | 2.8 million CHF (2019) |
| Branch | Pharma , research |
| Website | www.addexpharma.com |
| As of December 31, 2019 | |
The Addex Therapeutics Ltd , based in Plan-les-Ouates in Geneva is a Swiss biopharmaceutical undertakings incinerating or the allosteric modulators researched and developed. The company, founded in 2002 employs eight people and is listed on the Swiss Stock Exchange (since May 2007, Swiss Exchange ) listed .
Field of activity
The research and product development at Addex focuses on allosteric modulators of G protein-coupled receptors . The company has a pipeline of various product candidates, one of which is at an advanced stage. These are developed through partnerships with Merck & Co., Inc. and Johnson & Johnson .
The company's most advanced drug candidate is ADX10059 , a compound for the treatment of migraines and gastroesophageal reflux disease , and is in phase IIa.
Web links
- Addex Therapeutics website
- Company and trading data on the Swiss stock exchange (six-swiss-exchange.com)
Individual evidence
- ↑ a b Addex Therapeutics: Annual Report 2019. (pdf) Retrieved on May 23, 2020 (English).